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What is the mechanism for aripiprazole's effect on reducing olanzapineassociated obesity?
Abstract
We read with great interest Henderson and colleagues’ paper in your journal (2009; 29:165–169), which
reported that aripiprazole reduced olanzapine-induced overweight/obesity and hyperlipidemia in a
10-week placebo-controlled double-blind crossover study. This and their previous studies, provide a new
way for controlling olanzapine- and clozapine-induced weight gain/obesity using another atypical
antipsychotic, even without reducing the original olanzapine and clozapine doses, which is important
particularly for treatment of refractory schizophrenia patients. ....
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Editors,
We read with great interest Henderson and colleagues’ paper in your journal (2009;
29:165–169),

which

reported

that

aripiprazole

reduced

olanzapine-induced

overweight/obesity and hyperlipidemia in a 10-week placebo-controlled double-blind
crossover study. This and their previous studies 1,2 provide a new way for controlling
olanzapine- and clozapine-induced weight gain/obesity using another atypical
antipsychotic, even without reducing the original olanzapine and clozapine doses,
which is important particularly for treatment of refractory schizophrenia patients. The
key issue is what are the mechanisms that underlie aripiprazole’s effects on body
weight? Henderson et al. proposed that aripiprazole’s low histaminergic antagonism
and 5-HT2C agonist activity may contribute to its effect on reducing olanzapineinduced weight gain 1.

Several meta-analytical studies have indicated an association between histamine H1
antagonism properties in antipsychotic drugs and obesity side-effects

3,4

. Consistent

with these findings, both olanzapine and clozapine are potent H1 antagonists 5. A
recent study found that, correlated with body weight gain, olanzapine treatment
significantly down-regulated H1 receptor binding and mRNA expression in the rat
hypothalamus, however, aripiprazole did not affect H1 receptor expression 6. These
results suggest that aripiprazole’s effects in reducing olanzapine- and clozapineinduced weight gain/obesity should not be via H1 receptors, although histaminergic
antagonism is a main cause of olanzapine- and clozapine-induced weight gain/obesity.

We agree that 5-HT2C receptors may play a role, however, it should also be noted that
aripiprazole has only a moderate affinity to 5-HT2C receptors 7. Aripiprazole was

2

developed as a potent dopamine D2 partial-agonist, 5-HT1A partial agonist, and also
5-HT2A antagonist 7. A recent study has reported that both aripiprazole and olanzapine
affect 5-HT1A receptor expression, but these changes are not correlated with body
weight 8. On the other hand, like aripiprazole, olanzapine and clozapine are 5-HT2A
antagonists 5. Recent studies have suggested that aripiprazole is not a simple partial
agonist, but a functionally selective drug that can act as a D2 agonist or D2 antagonist
in different brain regions

9,10

. We suggest that aripiprazole’s D2 agonistic property

may account partly for the effect of aripiprazole in reducing olanzapine-induced
overweight /obesity. Atypical antipsychotics such as olanzapine may increase appetite
through the dopamine-mediated reward pathway 11. Dopamine D2 agonists have been
reported to reduce food intake by acting in hypothalamic areas 12.

Another possible mechanism of aripiprazole may be via the activation of the
PI3K/Akt pathway. The PI3K/Akt pathway plays an important role in cellular
proliferation, growth and metabolism

13

. Over-expression of the pathway causes

cancer but defects in the pathway could induce metabolic disorders. The PI3K/Akt
pathway plays a key role in the action of insulin via control of Glu4, which transports
glucose into the cells

14

. The activity of the PI3K/Akt pathway in insulin-mediated

Glu4 activation is impaired in olanzapine-induced obesity

15

. Aripiprazole may have

an effect on the activation of the PI3K/Akt pathway via its agonistic effect on D2
receptors. In fact, D2 receptor agonist (bromocriptine) has been reported to increase
the PI3K/Akt pathway activity

16

. It is possible that aripiprazole can restore the

impairment of the PI3K/Akt pathway in insulin-mediated Glu4 activation caused by
olanzapine so that the side-effect of weight gain is reduced. Further studies on these

3

mechanisms will improve our understanding and management of atypical
antipsychotic-induced weight gain/obesity.

References
1.

Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R,

Freudenreich O, Cather C, Evins AE, Goff DC. Aripiprazole added to overweight and
obese

olanzapine-treated

schizophrenia

patients.

Journal

of

Clinical

Psychopharmacology. 2009;29(2):165-9.
2.

Henderson DC, Kunkel L, Nguyen DD, Borba CP, Daley TB, Louie

PM, Freudenreich O, Cather C, Evins AE, Goff DC. An exploratory open-label trial
of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia.[see
comment]. Acta Psychiatrica Scandinavica. 2006;113(2):142-7.
3.

Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S,

Ernsberger P, Jayathilake K, Meltzer HY, Roth BL. H1-Histamine receptor affinity
predicts short-term weight gain for typical and atypical antipsychotic drugs.
Neuropsychopharmacology. 2003;28(3):519-526.
4.

Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based

analysis of the contributions of various receptors to antipsychotics-induced weight
gain and diabetes mellitus. Drug metabolism and pharmacokinetics. 2005;20(5):36878.
5.

Richelson E, Souder T. Binding of antipsychotic drugs to human brain

receptors focus on newer generation compounds. Life Sciences. 2000;68(1):29-39.

4

6.

Han M, Deng C, Burne THJ, Newell KA, Huang X-F. Short- and long-

term effects of antipsychotic drug treatment on weight gain and H1 receptor
expression.[see comment]. Psychoneuroendocrinology. 2008;33(5):569-80.
7.

DeLeon

A,

Patel NC,

Lynn Crismon

M.

Aripiprazole:

A

comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clinical
Therapeutics. 2004;26(5):649-666.
8.

Han M, Huang XF, du Bois TM, Deng C. The effects of antipsychotic

drugs administration on 5-HT1A receptor expression in the limbic system of the rat
brain. Neuroscience. 2009;164(4):1754-1763.
9.

Han M, Huang XF, Deng C. Aripiprazole differentially affects

mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term
drug efficacy and low extrapyramidal side-effects. International Journal of
Neuropsychopharmacology. 2009;12(7):941-952.
10.

Urban JD, Vargas GA, von Zastrow M, Mailman RB. Aripiprazole has

functionally selective actions at dopamine D2 receptor-mediated signaling pathways.
Neuropsychopharmacology. 2007;32(1):67-77.
11.

Elman I, Borsook D, Lukas SE. Food intake and reward mechanisms in

patients with schizophrenia: implications for metabolic disturbances and treatment
with

second-generation

antipsychotic

agents.[see

comment].

Neuropsychopharmacology. 2006;31(10):2091-120.
12.

Terry P, Gilbert DB, Cooper SJ. Dopamine receptor subtype agonists

and feeding behaviour. Obesity Research. 1995;3(Suppl. 4):515S-523S.
13.

Chen J. Is Src the key to understanding metastasis and developing new

treatments for colon cancer? Nature Clinical Practice. Gastroenterology &
Hepatology. 2008;5(6):306-307.

5

14.

Watson RT, Pessin JE. Intracellular organization of insulin signaling

and GLUT4 translocation. Recent Progress in Hormone Research. 2001;56:175-93.
15.

Dwyer DS, Donohoe D, Lu X, Aamodt EJ, Ronald J. Bradley

RAHaPJ. Mechanistic Connections between Glucose/Lipid Disturbances and Weight
Gain induced by Antipsychotic Drugs. International Review of Neurobiology:
Academic Press; 2005:211-247.
16.

Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Kanki R,

Yamashita H, Akaike A. Protective effect of dopamine D2 agonists in cortical
neurons via the phosphatidylinositol 3 kinase cascade. J Neurosci Res.
2002;70(3):274-82.

6

